Publications by authors named "Line Gutte Borgwardt"
Article Synopsis
- - Alpha-mannosidosis (AM) is a genetic disorder causing lysosomal enzyme deficiency, leading to the buildup of specific sugars; Velmanase alfa (VA) is the first enzyme replacement therapy targeting AM's non-neurological symptoms.
- - A study involving 33 patients on VA explored if genetic subgroups (G1, G2, G3) influenced antibody response (antidrug antibodies or ADAs) and related infusion reactions, finding that G1 and G2 were more likely to develop ADAs but most patients experienced mild or no infusion-related reactions.
- - Despite some patients developing ADAs, the overall treatment effects on serum oligosaccharides and clinical outcomes were similar across ADA-positive and ADA-negative
